NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Natural History Study of Kaposi Sarcoma

Recruiting

Conditions: Kaposi Sarcoma
HIV

First Posted Date: 2024-04-19

Last Posted Date: 2025-04-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 150

Registration Number: NCT06375122

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Phase 1

Recruiting

Conditions: Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Metastatic Gastroesophageal Junction Adenocarcinoma
Unresectable Gastric Carcinoma
Unresectable Gastroesophageal Junction Adenocarcinoma
Unresectable Malignant Solid Neoplasm
Clinical Stage III Gastric Cancer AJCC v8
Locally Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage IV Gastric Cancer AJCC v8
Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
Locally Advanced Gastric Carcinoma

Interventions: Drug: Azenosertib
Procedure: Biospecimen Collection
Procedure: Biopsy Procedure
Procedure: Computed Tomography
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Biological: Trastuzumab Deruxtecan

First Posted Date: 2024-04-15

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT06364410

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Phase 1

Recruiting

Conditions: B-Cell Chronic Lymphocytic Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
B-Lymphocytic Leukemia, Chronic

Interventions: Biological: Autologous HuCD19 ( Anti-CD19)CAR T cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2024-04-15

Last Posted Date: 2025-05-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 132

Registration Number: NCT06364423

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Multiple Myeloma
Refractory Lymphoma
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Crizotinib
Procedure: Radiologic Examination

First Posted Date: 2024-04-11

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06360575

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Phase 2

Active, not recruiting

Conditions: Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Copanlisib
Procedure: Radiologic Examination

First Posted Date: 2024-04-11

Last Posted Date: 2025-05-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT06360588

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

Phase 2

Active, not recruiting

Conditions: Refractory Multiple Myeloma
Advanced Malignant Solid Neoplasm
Advanced Lymphoma
Refractory Lymphoma
Hematopoietic and Lymphatic System Neoplasm
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Echocardiography Test
Procedure: Radionuclide Imaging
Drug: Vismodegib

First Posted Date: 2024-04-10

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06357988

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Drug: Crizotinib
Procedure: Radiologic Examination

First Posted Date: 2024-04-10

Last Posted Date: 2025-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT06357975

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

Phase 2

Active, not recruiting

Conditions: Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Erdafitinib
Procedure: Magnetic Resonance Imaging

First Posted Date: 2024-04-08

Last Posted Date: 2025-04-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06351371

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Phase 1

Recruiting

Conditions: Astrocytoma
Glioma
Recurrent Glioblastoma

Interventions: Radiation: Radiation Therapy

First Posted Date: 2024-04-03

Last Posted Date: 2025-02-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT06344130

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Phase 3

Recruiting

Conditions: Classic Follicular Lymphoma
Follicular Lymphoma With Unusual Cytological Features

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Biological: Mosunetuzumab
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human

First Posted Date: 2024-03-29

Last Posted Date: 2025-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 600

Registration Number: NCT06337318

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 183 locations

Home Terms & Conditions Privacy Policy